EA202190217A1 - Формы ивосидениба и фармацевтические композиции - Google Patents
Формы ивосидениба и фармацевтические композицииInfo
- Publication number
- EA202190217A1 EA202190217A1 EA202190217A EA202190217A EA202190217A1 EA 202190217 A1 EA202190217 A1 EA 202190217A1 EA 202190217 A EA202190217 A EA 202190217A EA 202190217 A EA202190217 A EA 202190217A EA 202190217 A1 EA202190217 A1 EA 202190217A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ivosidenib
- forms
- pharmaceutical compositions
- proposed
- preparations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694596P | 2018-07-06 | 2018-07-06 | |
| PCT/US2019/040257 WO2020010058A1 (en) | 2018-07-06 | 2019-07-02 | Ivosidenib forms and pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190217A1 true EA202190217A1 (ru) | 2021-04-16 |
Family
ID=69059942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190217A EA202190217A1 (ru) | 2018-07-06 | 2019-07-02 | Формы ивосидениба и фармацевтические композиции |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12264148B2 (enExample) |
| EP (2) | EP3817744A4 (enExample) |
| JP (2) | JP7621242B2 (enExample) |
| KR (2) | KR102919157B1 (enExample) |
| CN (1) | CN112367995A (enExample) |
| AU (2) | AU2019299352B2 (enExample) |
| BR (1) | BR112021000156A2 (enExample) |
| CA (1) | CA3103498A1 (enExample) |
| EA (1) | EA202190217A1 (enExample) |
| IL (2) | IL315423B1 (enExample) |
| MA (1) | MA53099A (enExample) |
| MX (2) | MX2021000068A (enExample) |
| PH (1) | PH12021550017A1 (enExample) |
| SG (1) | SG11202012763TA (enExample) |
| TW (2) | TWI911130B (enExample) |
| UA (1) | UA129800C2 (enExample) |
| WO (1) | WO2020010058A1 (enExample) |
| ZA (1) | ZA202008034B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020327013B2 (en) | 2019-08-08 | 2026-03-26 | Les Laboratoires Servier | A method for preparing Ivosidenib and an intermediate thereof |
| GB201912411D0 (en) * | 2019-08-29 | 2019-10-16 | Johnson Matthey Plc | Crystalline forms of ivosidenib |
| AR133410A1 (es) | 2023-08-01 | 2025-09-24 | Servier Lab | Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| RU2013144975A (ru) * | 2011-04-08 | 2015-05-20 | Пфайзер Инк. | Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| AR092439A1 (es) * | 2012-09-06 | 2015-04-22 | Bayer Healthcare Llc | Composicion farmaceutica recubierta que contiene regorafenib |
| MA39725B1 (fr) * | 2014-03-14 | 2021-09-30 | Les Laboratoires Servier Sas | Compositions pharmaceutiques de composés thérapeutiquement actifs |
| NZ723859A (en) * | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| KR102699521B1 (ko) * | 2015-10-15 | 2024-08-26 | 르 라보레또레 쎄르비에르 | 악성 종양의 치료를 위한 조합물 요법 |
| MA43640A (fr) * | 2016-02-26 | 2018-11-28 | Agios Pharmaceuticals Inc | Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides |
| US11066390B2 (en) | 2017-11-27 | 2021-07-20 | Assia Chemical Industries Ltd. | Solid state forms of Ivosidenib |
-
2019
- 2019-07-02 EA EA202190217A patent/EA202190217A1/ru unknown
- 2019-07-02 CN CN201980045552.5A patent/CN112367995A/zh active Pending
- 2019-07-02 EP EP19829932.3A patent/EP3817744A4/en not_active Withdrawn
- 2019-07-02 IL IL315423A patent/IL315423B1/en unknown
- 2019-07-02 JP JP2021500178A patent/JP7621242B2/ja active Active
- 2019-07-02 KR KR1020217000885A patent/KR102919157B1/ko active Active
- 2019-07-02 UA UAA202100436A patent/UA129800C2/uk unknown
- 2019-07-02 CA CA3103498A patent/CA3103498A1/en active Pending
- 2019-07-02 BR BR112021000156-5A patent/BR112021000156A2/pt unknown
- 2019-07-02 EP EP25187804.7A patent/EP4603147A3/en active Pending
- 2019-07-02 MX MX2021000068A patent/MX2021000068A/es unknown
- 2019-07-02 US US17/258,102 patent/US12264148B2/en active Active
- 2019-07-02 SG SG11202012763TA patent/SG11202012763TA/en unknown
- 2019-07-02 WO PCT/US2019/040257 patent/WO2020010058A1/en not_active Ceased
- 2019-07-02 AU AU2019299352A patent/AU2019299352B2/en active Active
- 2019-07-02 KR KR1020257038241A patent/KR20250164882A/ko active Pending
- 2019-07-02 MA MA053099A patent/MA53099A/fr unknown
- 2019-07-05 TW TW114126745A patent/TWI911130B/zh active
- 2019-07-05 TW TW108123796A patent/TWI902665B/zh active
-
2020
- 2020-12-22 ZA ZA2020/08034A patent/ZA202008034B/en unknown
- 2020-12-30 IL IL279877A patent/IL279877A/en unknown
-
2021
- 2021-01-04 PH PH12021550017A patent/PH12021550017A1/en unknown
- 2021-01-06 MX MX2023011687A patent/MX2023011687A/es unknown
-
2024
- 2024-08-08 JP JP2024131926A patent/JP2024150784A/ja not_active Withdrawn
-
2025
- 2025-05-23 AU AU2025203835A patent/AU2025203835A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UA129800C2 (uk) | 2025-08-06 |
| TWI911130B (zh) | 2026-01-01 |
| EP3817744A1 (en) | 2021-05-12 |
| MA53099A (fr) | 2021-05-12 |
| CA3103498A1 (en) | 2020-01-09 |
| AU2019299352A1 (en) | 2021-01-07 |
| ZA202008034B (en) | 2021-10-27 |
| KR102919157B1 (ko) | 2026-01-27 |
| US20210323944A1 (en) | 2021-10-21 |
| TW202019419A (zh) | 2020-06-01 |
| IL315423B1 (en) | 2026-04-01 |
| TWI902665B (zh) | 2025-11-01 |
| TW202543623A (zh) | 2025-11-16 |
| AU2019299352B2 (en) | 2025-02-27 |
| KR20210029775A (ko) | 2021-03-16 |
| PH12021550017A1 (en) | 2021-09-13 |
| EP3817744A4 (en) | 2022-07-13 |
| JP2024150784A (ja) | 2024-10-23 |
| MX2023011687A (es) | 2023-10-19 |
| EP4603147A3 (en) | 2025-10-01 |
| IL279877A (en) | 2021-03-01 |
| AU2025203835A1 (en) | 2025-06-12 |
| JP2021529805A (ja) | 2021-11-04 |
| CN112367995A (zh) | 2021-02-12 |
| SG11202012763TA (en) | 2021-02-25 |
| JP7621242B2 (ja) | 2025-01-24 |
| BR112021000156A2 (pt) | 2021-04-06 |
| MX2021000068A (es) | 2021-03-25 |
| WO2020010058A1 (en) | 2020-01-09 |
| US12264148B2 (en) | 2025-04-01 |
| IL315423A (en) | 2024-11-01 |
| EP4603147A2 (en) | 2025-08-20 |
| KR20250164882A (ko) | 2025-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891083A1 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
| MX390014B (es) | Compuestos de dinucleótidos cíclicos y métodos de uso. | |
| BR112018073761A2 (pt) | proteínas de ligação ao cd3 de fragmento variável de cadeia única | |
| MX380753B (es) | Lactamas bicíclicas y métodos de uso de las mismas. | |
| EA201890052A1 (ru) | Регуляторы nrf2 | |
| EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
| EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
| CO2021011906A2 (es) | Anticuerpos claudina 6 y usos de los mismos | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| EA202191114A1 (ru) | Производные пиридинилсульфонамида, фармацевтические композиции и их применение | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201791896A1 (ru) | Дезацетокситубулизин н и его аналоги | |
| EA202090978A1 (ru) | Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202191515A1 (ru) | Фармацевтическая композиция, содержащая апиксабан | |
| EA201792000A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
| EA201791992A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды | |
| EA202190217A1 (ru) | Формы ивосидениба и фармацевтические композиции | |
| PH12020551618A1 (en) | Erenumab compositions and uses thereof | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| EA202191403A1 (ru) | Композиция с высокой концентрацией белка | |
| MX2020013389A (es) | Composiciones de terlipresina y usos de las mismas. | |
| EA201890177A1 (ru) | Мультиспецифические связывающие белки |